Home  Partnering Key areas of partnering interest
|
|
| Cardiovascular & Gastrointestinal |
| Key areas of partnering interest |
|
|
| Diabetes and Obesity |
|---|
Oral diabetes segment
- Insulin sensitisers
- Glucose dependent insulin secretagogues (oral GLP-1, PTP-1b)
- Beta cell protection/regeneration
- Compounds should have beneficial or neutral effect on other CV risk factors, including body weight
Step-change insulins and management
- Non-injectable administration (oral, inhalation or transdermal)
- Non-invasive glucose monitoring
Injectable diabetes segment
- Beta cell protection/regeneration
- Glycaemic control and weight loss
Obesity
- Novel mechanism for weight loss/prevention of weight gain including appetite and/or energy expenditure
- Early stage opportunities with proof of concept in pre-clinical models
- Good safety profile |
Atherosclerosis |
|---|
Technical/Discovery
- Biochemical markers, imaging technologies and relevant animal models to study the vulnerable plaque
Target Areas
- Reversed cholesterol transport by increasing ApoA1, HDL or other relevant mechanism
- Anti-inflammatory compounds relevant to plaque stability (adhesion molecules)
- Parental compounds for high risk atherosclerosis patients (i.e. ApoA1 mimetics) |
Thrombosis |
|---|
Anti-coagulation
- Factor Xa programmes with a predictable effect base on low variability in PK/PD
Anti-platelets
- Improved efficacy especially for ACS patients
- Predictable action
- Rapid onset and offset |
Other Cardiovascular Area |
|---|
| Oral atrial fibrillation agents with clinical proof of concept |
Gastrointestinal |
|---|
Treatments in Gastroesophageal reflux disease other than acid secretion inhibition
Novel treatments of GI diseases that have passed clinical concept testing |
Pre-clinical: magnus.bjorsne@astrazeneca.com
Clinical: andy.yates@astrazeneca.com
|
|
|
|